



Ah Receptor-Mediated Disruption of the Cardiac Embryogenesis Program

Alvaro Puga

Department of Environmental Health


University of Cincinnati College of Medicine, Ohio.

Congenital Heart Disease

Most prevalent form of human birth defect

- 30% of prenatal loss
- 0.4%–5% of live births
- Most common: VSD
- High economical burden
- \$1.4 billion hospitalization cost per year (2013)

Leading cause of adult cardiac insufficiency



Source: texasheart.org

Etiology of Congenital Heart Disease

Genetic (explaining only ~15% of cases - CDC)

- Gene mutations

- » *Cited2, Ets1, Foxh1, Gata4, Gata6, Hand1, Hand2, Hoxa1, Irx1, Nkx2-5, Nkx2-6, Pitx2 and Tbx1*

Environmental


- Metabolic
- Infectious
- Xenobiotics

- » *Persistent organic pollutants (POP)*



At risk...

- Gestation in areas with high industrial, natural, or accidental release of POPs (e.g. dioxins)
- Important
 - Maternal lifelong dietary exposure to dioxins and dioxin-like compounds



BIRTH DEFECTS RECOGNIZED BY THE VA AS CONNECTED TO AGENT ORANGE EXPOSURE

Spina Bifida: children born to either male or female Vietnam veterans; Spina Bifida Occulta not included

CHILDREN BORN TO FEMALE VIETNAM VETERANS


Achondroplasia: produces a type of dwarfism

Cleft Lip and Cleft Palate

Congenital Heart Disease


+18 other diseases – VA Association

Dioxins are potent agonists of the aryl hydrocarbon receptor (AHR)



- Dioxin (TCDD/TCDF) and Dioxin-like (PCBs)
 - At least 300-400 toxic compounds
- Dioxins share:
 - Structural relationship
 - Environmental persistence and bioaccumulation
 - Bind to and elicit AHR-dependent biochemical/toxic response


Biological processes regulated by the naïve AHR




Outline

- AHR modulates lineage specification pathways during early differentiation
 - *Loss of pluripotency*
 - *Cardiogenesis*
 - *Neuroglia*
- Dioxin exposure and *Ahr* ablation disrupt cardiogenesis
 - *Short and long-term effects of developmental dioxin exposure*
- Gene-environment interactions in cardiac disease
 - *Ahr –Nkx2.5 interactions in cardiac haploinsufficiency*

The preimplantation *Ahr* gene is silent



The *Ahr* gene is repressed in ES cells





12 - 15% of the ES cell population expresses AHR



AHR

Merge



T1
(*Ahr*^{-/-})




C2
(*Ahr*^{+/+})





Relative fluorescence intensity




AH
Cyp1a1-
promoter





BA
 β actin-
promoter




Fluctuating state of AHR expression in ES cells




Pluripotency factors are down-regulated in AE cells





AE cells proliferate more slowly and accumulate in G2/M




AHR modulates mitotic progression and pluripotency



AE cells promote unsustained neuroglia differentiation



Mouse ES cells form embryoid bodies




Day 3

Day 4

that differentiate into
beating cardiomyocytes




Not the embryoid bodies
formed by AE cells




Outline

- AHR modulates lineage specification pathways during early differentiation
 - *Loss of pluripotency*
 - *Cardiogenesis*
 - *Neuroglia*
- **Dioxin exposure and *Ahr* ablation disrupt cardiogenesis**
 - *Short and long-term effects of developmental dioxin exposure*
- Gene-environment interactions in cardiac disease
 - *Ahr –Nkx2.5 interactions in cardiac haploinsufficiency*



Ahr expression is up-regulated
as ES cells differentiate




Cardiomyocyte differentiation has a narrow window of TCDD sensitivity



TGF β 1 restores contractility blocked by TCDD




The AHR/TCDD axis interferes at multiple developmental stages with the differentiation of contractile cardiomyocytes




First organ

Dosing scheme—*in vivo* analyses


Organogenesis



What are the gene expression effects of AHR disruption?




AHR disruption affects the expression of key networks involved in cardiogenesis, cardiac homeostasis, and mitochondrial function



TCDD at E9.5 0 - E11.5
RNA.seq right atrium
at E15.5


TCDD
Ahr^{-/-}
Common

Gene networks common and not-common to *Ahr* KO and TCDD exposure




Genes deregulated at E15.5


Mitochondrial Pathway Genes



Oxidative Phosphorylation Genes




TCA Cycle Genes




Developmental AHR disruption globally downregulates mitochondrial complexes

Mitochondrial Dysfunction at E15.5 *Ahr*^{-/-}




Developmental AHR disruption globally downregulates mitochondrial complexes






Mitochondrial Dysfunction at E15.5 $Ahr^{+/+}$ + TCDD



Developmental AHR disruption affects mitochondria structure and abundance





Decline of cardiovascular performance in TCDD-exposed E15.5 embryos determined by very high frequency echosonography



Gene expression changes remain 9 months later


Mitochondrial Pathways Genes

Oxidative Phosphorylation Genes




Treadmill endurance test of *Ahr*^{-/-} and *Ahr*^{+/+} mice exposed or not to TCDD *in utero*

Treadmill Endurance Test Outcome



Time to Failure





Outline

- AHR modulates lineage specification pathways during early differentiation
 - *Loss of pluripotency*
 - *Cardiogenesis*
 - *Neuroglia*
- Dioxin exposure and *Ahr* ablation disrupt cardiogenesis
 - *Short and long-term effects of developmental dioxin exposure*
- **Gene-environment interactions in cardiac disease**
 - *Ahr –Nkx2.5 interactions in cardiac haploinsufficiency*

The molecular signature of developmental AHR disruption is similar to the *Nkx2-5*^{-/-} heart transcriptome


<i>Nkx2-5</i> ^{-/-} gene expression (Prall et al 2007)	<i>Ahr</i> ^{+/+} + TCDD		<i>Naïve Ahr</i> ^{-/-}	
Downregulated	Direction	Agrees <i>Nkx2-5</i> mutant	Direction	Agrees <i>Nkx2-5</i> mutant
Ankrd1	up	no	unchanged	no
Nppb (Bnp)	down	yes	down	yes
Nr2f2 (coup TFII)	up	no	up	no
Myl2	down	yes	down	yes
Irx4	down	yes	down	yes
Smpx (Chisel)	unchanged	no	down	yes
Nppa (Anf)	up	no	up	no
Wnt11	up	no	up	no
Upregulated				
IGFBP5	up	yes	up	yes
Pdgfra	up	yes	up	yes
Tnc	up	yes	up	yes
Isl1	up	yes	up	yes
Tbx5	up	yes	up	yes
Bmp2	unchanged	no	unchanged	no
Fgf10	up	yes	up	yes
Hhex	unchanged	no	unchanged	no
Unaltered				
Cer1	unchanged	yes	unchanged	yes
Dan	unchanged	yes	unchanged	yes
NOG	unchanged	yes	unchanged	yes
Bmp4	up	no	up	no
Bmp7	down	no	down	no
Dkk1	unchanged	yes	unchanged	yes

Loss of *Ahr* or TCDD exposure repress NKX2-5




B

C




Heart-specific *Ahr* knockout with a *Nkx2-5^{+/cre}* knockin



The genotype of these mice is *Nkx2-5^{+/cre} Ahr^{fx/fx}*

Because they have only one functional *Nkx2-5* allele
These mice are haploinsufficient

Ahr ablation rescues NKX2.5-dependent cardiac insufficiency



Congenital Cardiac Disease

NKX2.5 ← *AHR* → Environment

Congenital cardiac malformations

Valvular stenosis

Hypoplastic left heart syndrome

8 per 1000 live births

25 - 30% of cardiac disease

Deadly if not surgically repaired at birth

I hope that I have convinced you that ...


The *Ahr* gene is positively silenced in ES cells

Ahr modulates lineage specification pathways during early differentiation

Ahr ablation and dioxin exposure disrupt cardiomyocyte differentiation

Gene networks, Mitochondria, OXPHOS, Heart function, Endurance


Ahr reinforces *Nkx2.5*-dependent haploinsufficiency



Physiological Roles


AHR

Toxicological Outcomes



Ligand mediated toxicity

Many transcription factors are disrupted by TCDD in ES cells



AHR disruption during development alters the structure of the adult myocardium

